MAOI Diet Abbreviated 3.3
Dr P Ken Gillman V 3.3 (2018)
- For people who already follow healthy eating (and drinking) amounts a low tyramine diet involves very few changes
- Only some foods that have gone ‘off’, or those prepared using maturation and ‘fermenting’ techniques, can sometimes have high tyramine (less common with modern foods)
- The increased blood pressure reaction that can result from excess tyramine ingestion is proportional to the amount of tyramine ingested
- Nowadays very few foods or drinks have tyramine levels sufficiently high that a small amount (i.e. 50 grams or ml, or less) is likely to cause a problematic degree of hypertension
- All modern cheeses are safe in healthy-sized portions (25-50 grams). Only a very few matured cheeses can sometimes have higher tyramine concentrations, so a little care and awareness is still needed
- Reaction to modern foods are likely to be mild and to last less than 2 hrs. The chance of coming to serious harm is remote
- The symptoms of a reaction are: a thumping forceful heartbeat (usually a slower than normal pulse rate), paleness (pallor), rapid onset severe headache, tightness in the chest. Pulse may drop as low as 40 beats per minute
- The variability of sensitivity to tyramine between individuals means that a small percentage of people may notice mild reactions with smaller doses
- It is useful to monitor your own blood pressure, sitting & standing see: https://www.psychotropical.com/wp-content/uploads/2018/05/4-MAOIs-Blood-pressure.pdf
- Drugs: SSRIs and SNRIs are absolutely contra-indicated. Some cough and cold remedies are also to be avoided — see below for details.
This is an abbreviated version of the full monograph which may be studied by those requiring more detailed information: it has full details of the tyramine content of a large range of foods and detailed explanations of drug interactions.
Interactions between monoamine oxidase inhibitors (MAOI) and other drugs are now well understood  and there is more data on the tyramine in foods, and also on how much is likely to constitute a problem . Concentrations are given as milligrams (mg) of tyramine per kilogram (kg) or litre (L).
For those who already follow healthy eating amounts and patterns an MAOI low tyramine diet involves almost no changes at all.
There is some variation of tyramine sensitivity between individuals. Therefore, a small proportion of people may get a measurable, but not problematic, blood pressure rises with only 10 mg of tyramine, but most people need to have 25-50 mg (in a meal) to get a significant rise in BP. For a detailed analysis of the evidence relating to tyramine dose and blood pressure see refs [1, 3] and the full monograph.
Learn what 10 g or 100 g of cheese looks like. Healthy amounts of cheese are around what is safe tyramine-wise: very few contain more than 25 mg/100 grams, so a large 50 g portion (a ‘healthy’ portion is 25 g) contains only 12 mg of tyramine and that is not a problem, even in tyramine-sensitive individuals.
Monitor blood pressure while on MAOIs: buy a BP monitor (upper arm or wrist type).
Even if excessive tyramine is ingested and BP increase occurs, serious consequences are very unlikely. The appropriate action is to monitor BP for 1-2 hours. Hasty treatment of high BP by inexperienced Doctors risks doing more harm than good. That should only be undertaken in hospital [1, 3, 4]. Sub-lingual nifedipine should not be used; an effective dose of a benzodiazepine like ‘Valium’ is all that is likely to be required: see full monograph for details of advice about treatment of hypertensive episodes (urgencies). There is a PDF explaining blood pressure monitoring. There are two main reasons for BP monitoring:
1) variation in the population: some people will get more marked reactions of BP elevation with relatively smaller doses of tyramine. It will tell you if you are tyramine sensitive and alert you to the need to be careful about diet
2) BP drop on standing is the best measure of the effectiveness of a given dose and essential to optimal speed of adjustment to the final effective dose (see info re an App for mobiles that makes a graph of your BP readings).
These drugs are called Mono-Amine Oxidase Inhibitors (MAOIs). This covers both food and drink, and drug interactions, for those taking MAOIs.
Keep some means of identifying the fact that people are on MAOIs, like with insulin, or epilepsy.
Advice on MAOIs should ideally come from specialist psycho-pharmacologists, most general psychiatrist have limited knowledge about MAOIs, but advice and assistance is available via the Google group set up to support and advise doctors (Doctors may join by applying for membership via email address below).
I have published various papers on the pharmacology of MAOIs and their interactions, see: [1, 3, 5-12].
Tyramine formation in foods requires the presence of particular micro-organisms with ‘amino acid decarboxylase’ enzyme-activity. It can only build up to potentially significant levels in foods that are ‘fermented’ deliberately using micro-organisms: e.g. some cheeses, soy sauces, salami-type sausages.
Modern food production techniques have virtually eliminated such bacteria from the ‘starter-cultures’ that are used for making cheeses, salamis, soy sauces etc. ‘Fresh’ food cannot have significant tyramine unless it has been badly contaminated and then stored without being properly chilled: and modern regulations and practices governing the food supply chain make that highly improbable.
A reaction is an increase of BP over 30 – 60 minutes and usually shows first as a forceful thumping heartbeat. Pulse usually becomes slower . If blood pressure goes up to 180 mm Hg or more severe headache is usual. Tightness in the chest, paleness (pallor) may occur. Symptoms may last for about two hours.
Few foods, except cheese, have high tyramine and any BP reaction is proportional to the amount that is consumed: it is a dose-related effect.
For detailed data and references see full monograph.
Most cheeses now have low tyramine levels (<10 mg/kg), whether they are hard, semi-hard, acid-curd or soft [14-19], that includes almost all commercial lower priced “processed” and “supermarket” cheeses whose tyramine levels are <200 mg/kg, usually in the range of 0-50 mg/kg).
These are non-matured cheese styles released after 2-4 weeks and have low tyramine levels. Examples from Austria, Holland and France had max levels of 85 mg/kg with undetectable levels in most .
Parmigiano Reggiano, aged 30 months, tyramine 20-150 mg/kg .
Cheddar, most <50 mg/kg, and even at 36 weeks maturation all were <160 mg/kg .
Gouda, tyramine 100 – 250 mg/kg, Gruyere, tyramine < 100 mg/kg, Emmental, tyramine 0 – 68 mg/kg [15, 17].
Most cheeses have <250 mg/kg of tyramine, so a healthy serving of 25 g has ~6 mg of tyramine, which is perfectly safe.
Unripened cheese styles: these have no tyramine, e.g. curd styles, fromage frais, mascarpone, cream, ricotta, mozzarella, cottage cheeses, bocconcini. Mozzarella, Ricotta. Multiple samples, tyramine, 0 mg/kg . Milk and yoghurt: no tyramine.
It is likely that changes in the way these products are now prepared have lowered the tyramine content; Marmite level ~320 mg/kg of tyramine . A teaspoon of ‘Marmite’ would have only a couple of mg, perfectly safe.
Most supermarket Soy sauces have less than 200 mg/l. Normal ‘condiment’ quantities (10-20 ml) therefore would have <5 mg and are safe . Note: unfermented soybean products, like most types of tofu, have no tyramine.
Fresh and frozen meat and meat products are safe. Fresh liver has no tyramine , but can spoil quickly if refrigerated badly (i.e. >4 deg.). Similarly, liver pate (and similar meat or fish pastes) are safe if properly refrigerated.
Dry cured products: Parma ham, prosciutto etc are safe, max 15 mg/kg .
Improved starter cultures result in much diminished tyramine content [25, 26].
Most salami types are <100 mg/kg. Therefore a ‘normal’ portion of 50 g will have no more than 5 mg.
It depends what you put on it. But (see cheese and salami above) many pizzas use mozzarella, which has no tyramine.
Wine is safe. Modern hygienic production methods have made excessive tyramine concentrations rare (in both wine and beer). A little caution is warranted with ’boutique’ and open fermented beers, rare examples can be high.
Myth: MAOIs have many dangerous interactions with other drugs.
Yet there are only two interactions: just SRIs and releasers (ISAs).
The potentially risky interactions with MAOIs are:
Serotonin syndrome, caused by (S)SRIs + MAOIs
Blood pressure elevation, caused by tyramine in food, or by the other releasers like ephedrine & pseudoephedrine.
Any drug that works as a serotonin reuptake inhibitor (SRI) is potentially dangerous (possibly fatal) if combined with an MAOI [6, 27] including:-sertraline, fluoxetine, paroxetine, fluvoxamine, citalopram, escitalopram, clomipramine or imipramine, or SNRIs like milnacipran, venlafaxine, desvenlafaxine, duloxetine.
NB It is usually stated that all TCAs pose a risk, but that is definitely not correct, it is only clomipramine and imipramine.
On ceasing other antidepressants to start MAOIs, washout intervals varying between one and five weeks may be required. No washout is required for TCAs (other than clomipramine and imipramine), or mirtazapine, mianserin, trazodone or reboxetine, because they are safe taken together with MAOIs.
The risk is that of serotonin toxicity (ST), because some act as SRIs, as explained in detail in my review , pethidine (aka meperidine) and tramadol, especially, are a significant risk for anyone on MAOIs. Dextromethorphan, (dextro)propoxyphene and pentazocine are also best avoided.
It is safe to have an anaesthetic whilst on MAOIs.
It is safe to have adrenalin at the dentist.
This advice on diet and possible interacting drugs should be followed for a minimum of two weeks (six weeks in some situations) after ceasing MAOIs (between one and three days in the case of moclobemide).
1. Gillman, P.K., Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. Journal of Clinical Psychopharmacology, 2011. 31(1): p. 66-74.
2. Finberg, J. and P. Gillman, Pharmacology of MAO-B inhibitors and the cheese reaction, in International Review of Neurobiology, M. Youdim and P. Riederer, Editors. 2011, Elsevier Inc. Academic Press.: Burlington. p. 169-190.
3. Gillman, P.K., A reassesment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. Journal of Neural Transmission, 2018: p. in press.
4. Flanigan, J.S. and D. Vitberg, Hypertensive emergency and severe hypertension: what to treat, who to treat, and how to treat. Med Clin North Am, 2006. 90(3): p. 439-51.
5. Gillman, P.K., More on Mrs Murphy’s beans: or ‘do us a fava’. Journal of Clinical Psychopharmacology, 2010. 30(2): p. 215-216.
6. Gillman, P.K., Combining antidepressants: Understanding Drug Interactions is the Sine Qua Non. Advances in Psychiatric Treatment, 2010. 16: p. 76-78.
7. Gillman, P.K., CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. Journal of Psychopharmacology, 2011. 25(3): p. 429-3.
8. Gillman, P.K., Ti: myths about monoamine oxidase inhibitors perpetuated. Australian and New Zealand Journal of Psychiatry, 2009. 43(11): p. 1084-5.
9. Gillman, P.K., Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology 2007. 151(6): p. 737-48.
10. Gillman, P.K., A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status. Human Psychopharmacology. Clinical and Experimental, 2006. 21(2): p. 117-25.
11. Gillman, P.K., A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biological Psychiatry, 2006. 59(11): p. 1046-51.
12. Gillman, P.K., Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 2005. 95(4): p. 434-441.
13. Bar-Am, O., et al., Cardiovascular baroreceptor activity and selective inhibition of monoamine oxidase. Eur J Pharmacol, 2012. 15(683): p. 226-30.
14. Fiechter, G., G. Sivec, and H.K. Mayer, Application of UHPLC for the simultaneous analysis of free amino acids and biogenic amines in ripened acid-curd cheeses. J Chromatogr B, 2013. 927: p. 191-200.
15. Mayer, H.K., G. Fiechter, and E. Fischer, A new ultra-pressure liquid chromatography method for the determination of biogenic amines in cheese. Journal of Chromatography A, 2010. 1217: p. 3251–3257.
16. Bunkova, L., et al., The effect of ripening and storage conditions on the distribution of tyramine, putrescine and cadaverine in Edam-cheese. Food Microbiol, 2010. 27(7): p. 880-8.
17. Spizzirri, G.U., et al., Determination of biogenic amines in different cheese samples by LC with evaporative light scattering detector. Journal of Food Composition and Analysis, 2013. 29: p. 43–51.
18. Palermo, C., et al., A multiresidual method based on ion-exchange chromatography with conductivity detection for the determination of biogenic amines in food and beverages. Anal Bioanal Chem, 2013. 405(2-3): p. 1015-23.
19. Linares, D.M., et al., Factors Influencing Biogenic Amines Accumulation in Dairy Products. Front Microbiol, 2012. 3: p. 180.
20. Rea, M.S., et al., Development of enterococci and production of tyramine during the manufacture and ripening of Cheddar cheese. Irish Journal of Agricultural and Food Research, 2004. 43: p. 247–258.
21. Populin, T., et al., A survey on the presence of free glutamic acid in foodstuffs, with and without added monosodium glutamate. Food Chemistry, 2007. 104: p. 1712-1717
22. Yongmeia, L., et al., Biogenic amines in Chinese soy sauce. Food Control, 2009. 20: p. 593-597.
23. Krausová, P., et al., Content of biologically active polyamines in livers of cattle, pigs and chickens after animal slaughter. Meat Science, 2006. 73: p. 640-644.
24. Papavergou, E.J., I.N. Savvaidis, and I.A. Ambrosiadis, Levels of biogenic amines in retail market fermented meat products. Food Chem, 2012. 135(4): p. 2750-5.
25. Leggio, A., et al., Dry fermented sausages of Southern Italy: a comparison of free amino acids and biogenic amines between industrial and homemade products. J Food Sci, 2012. 77(4): p. S170-5.
26. Latorre-Moratalla, M.L., et al., Control of biogenic amines in fermented sausages: role of starter cultures. Front Microbiol, 2012. 3: p. 169 doi: 10.3389/fmicb.2012.00169. eCollection 2012.
27. Gillman, P.K., Moclobemide and the risk of serotonin toxicity (or serotonin syndrome). Central Nervous System Drug Reviews, 2004. 10: p. 83-85.